A chemotherapy-free, MRD-driven strategy using acalabrutinib and lenalidomide with rituximab or obinutuzumab shows promise for untreated MCL patients, offering high response rates and manageable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results